title: Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors.
abstract: Pre-existing immunity against adeno-associated virus (AAV) remains a major challenge facing the clinical use of systemic administration of recombinant AAV vectors for the treatment of genetic and acquired diseases using gene therapy. In this study, we evaluated the potential of bortezomib (marketed under trade name Velcade) to abrogate a pre-existing immunity to AAV in mice, thereby allowing subsequent transduction by a recombinant AAV vector of the same serotype. We demonstrate that bortezomib efficiently reduces AAV-specific IgG titres and moderates the cytotoxic T cell response in mice that have a pre-existing immunity to AAV2/8. Significant depletion of AAV2/8-specific IgG-producing plasma cells in secondary lymphoid organs and bone marrow was observed. However, this inhibition of the immune response by bortezomib was insufficient to allow subsequent re-infection with a recombinant AAV vector of a similar serotype. We show that this shortcoming is probably due to the combination of residual antibody levels and the inability of bortezomib to completely deplete the memory B cells that are re-activated in response to a repeated infection with a recombinant AAV vector. Taken together, the results of this study argue for the use of immunosuppressive therapies that target both plasma and memory B cells for the efficient elimination of pre-existing immunity against AAV2/8 vectors.
authors.affiliation: Genetic Disease Science, Genzyme Corporation, Framingham, Massachusetts, United States of America. jozsef.karman@genzyme.com
authors.forename: Jozsef
authors.initials: J
authors.lastname: Karman
authors.forename: Nathan K
authors.initials: NK
authors.lastname: Gumlaw
authors.forename: Jinhua
authors.initials: J
authors.lastname: Zhang
authors.forename: Ji-Lei
authors.initials: JL
authors.lastname: Jiang
authors.forename: Seng H
authors.initials: SH
authors.lastname: Cheng
authors.forename: Yunxiang
authors.initials: Y
authors.lastname: Zhu
mesh_terms: D000818:Animals; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D016207:Cytokines / Q000378:metabolism; D000229:Dependovirus / Q000276:immunology*; D005434:Flow Cytometry; D005822:Genetic Vectors / Q000276:immunology*; D007109:Immunity / Q000187:drug effects*; D008297:Male; D051379:Mice; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000494:pharmacology*
chemical_list: D001897:Boronic Acids; D016207:Cytokines; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib